Founded in 2007, Curetis focuses on creating reliable, fast, and cost-effective syndromic testing products for diagnosing severe infectious diseases. Their diagnostic solution, Unyvero, enables rapid detection of multiple pathogens and antibiotic resistance markers in just a few hours, significantly reducing the time compared to other techniques that can take days or weeks. The Unyvero platform offers a wide range of applications, including Hospitalized Pneumonia, Blood Culture Infection, Implant & Tissue Infections, Intra-Abdominal Infections, and Urinary Tract Infections. Based in Holzgerlingen, Germany, Curetis has established international distribution agreements across Europe, the Middle East, and Asia. In 2017, they also launched Ares Genetics GmbH, a subsidiary dedicated to maximizing R&D opportunities for the entire Curetis Group.